Potential biosimilars savings in EU5 and U.S. 2016-2020

This statistic shows the potential cumulative savings due to the introduction of biosimilars for 8 key products combined in EU-5 countries and the U.S. between 2016 and 2020. Until 2017, assuming a price reduction of 20 percent for the 8 key products' biosimilars, savings would reach around 9 billion U.S. dollars.

Potential savings due to biosimilars for 8 key products combined in EU-5 countries and the U.S. between 2016 and 2020 (in billion euros)*

Characteristic	20% price reduction	30% price reduction	40% price reduction
-	-	-	-
-	-	-	-
-	-	-	-
-	-	-	-
-	-	-	-

Download

Source

Show detailed source information?

Already a member?

Sources

Use Ask Statista Research Service

Release date

September 2016

More information

Region

United States, EU

Survey time period

as of December 2015

Supplementary notes

* Savings potential in EU5+US biosimilar accessible market dependent on change in price per treatment day. The accessible market analysis is based on Adalimumab, Insulin glargine, Etanercept, Infliximiab, Rituximab, Peg-filgrastim, Trastuzumab and Follitropin alpha. Savings potential in biosimilar accessible market at different price levels is calculated based on extrapolated size of the originator market between 2016 and 2020 based on historic CAGR and analogues. Accumulation of savings potential between 2016-2020 is shown.
EU-5 includes Germany, UK, France, Italy, and Spain.

Citation formats